Today we’re pleased to announce that we’ve received the necessary regulatory approvals making it possible to export and distribute Tilray medical cannabis in Chile. We’re proud to now have a presence on four continents around the world.
Tilray is partnering with Alef Biotechnology to import and distribute Tilray products in the country. Alef is licensed by the Chilean government to commercially produce medical cannabis. Chilean law permits patients to access medical cannabis products under the supervision of a recommending physician. Currently, there are an estimated 88,000 Chilean patients suffering from a diverse range of conditions who could benefit from medical cannabis. The first shipment of Tilray products is expected to arrive in Chile by the end of February and will initially be available at select hospitals and pharmacies in Santiago.
Tilray currently supplies pharmaceutical-grade medical cannabis products, including whole flower and oils, to thousands of patients, physicians, pharmacies, hospitals, governments and researchers around the world.
Tilray became the first medical cannabis producer in North America to be GMP certified in December 2016. GMP certification is the most rigorous standard that manufacturers of medical products must meet in their production processes, and it provides regulators and health care providers in countries new to medical cannabis with certainty that Tilray products are the safe and smart choice.
GMP certification is enabling Tilray to expand international distribution of its products. In 2016, Tilray made history by becoming the first company to legally export medical cannabis products from North America to Australia and the European Union. In 2017, the company is focused on expanding global distribution of its products to additional countries in Europe and Latin America.
GMP certification is also allowing Tilray to continue to break new ground in clinical research, advancing the science of medical cannabis for patients with a diverse range of conditions. Tilray currently supplies pharmaceutical-grade medical cannabis products for three different clinical trials in partnership with world-leading hospitals and universities, including the University of British Columbia, the University of Sydney and Toronto’s Hospital for Sick Children.
We plan to announce additional research partnerships in the coming year.